Department of Internal Medicine, Hallym University Medical Center, Seoul, Korea.
Am J Cardiol. 2010 Jun 15;105(12):1723-7. doi: 10.1016/j.amjcard.2010.01.351. Epub 2010 Apr 27.
Transradial coronary artery angiography (TRCAG) can have harmful effects on the radial artery as a conduit for coronary artery bypass graft surgery. The aim of this study was to evaluate the effects of trimetazidine (TMZ) on the functional recovery of the radial artery in patients who underwent TRCAG with flow-mediated dilation (FMD). Sixty patients, who underwent TRCAG using a 5Fr sheath were randomly assigned to the TMZ group or the control group. Baseline, post-TRCAG (<24 hours after TRCAG), and 10-week follow-up FMD were performed. In the control group of the cannulated arm, the baseline FMD was 11.4 +/- 3.5%, but the post-TRCAG FMD was significantly decreased to 4.2 +/- 2.9% (p <0.01). At 10-week follow-up, FMD was still decreased compared to baseline FMD (11.4 +/- 3.5% vs 5.9 +/- 3.3%, p <0.01). In the TMZ group of the cannulated arm, the difference in FMD between baseline and post-TRCAG was also significant (11.3 +/- 3.5% vs 6.3 +/- 4.0%, p <0.01). However, at 10-week follow-up, FMD was improved to 10.4 +/- 3.4%, and there was no difference in FMD between baseline and 10-week follow-up (11.3 +/- 3.5% vs 10.4 +/- 3.4%, p = 0.26). Repeated-measures analysis of variance confirmed the significance of the differences in FMD between the TMZ group and the control group (p <0.01). In conclusion, TMZ therapy after TRCAG reduced the endothelial dysfunction of the radial artery. This could contribute to positive effects for the radial artery conduit after coronary artery bypass graft surgery.
经桡动脉冠状动脉造影(TRCAG)作为冠状动脉旁路移植术的血管通路,可能对桡动脉产生有害影响。本研究旨在评估曲美他嗪(TMZ)对经桡动脉冠状动脉造影后血流介导的桡动脉舒张功能(FMD)恢复的影响。60 例接受 5Fr 鞘管 TRCAG 的患者随机分为 TMZ 组和对照组。在基线、TRCAG 后(TRCAG 后<24 小时)和 10 周随访时进行 FMD 检查。在对照组的穿刺侧手臂中,基线 FMD 为 11.4 ± 3.5%,但 TRCAG 后 FMD 显著降低至 4.2 ± 2.9%(p <0.01)。在 10 周随访时,FMD 仍低于基线 FMD(11.4 ± 3.5% vs 5.9 ± 3.3%,p <0.01)。在 TMZ 组的穿刺侧手臂中,基线和 TRCAG 后 FMD 之间的差异也有统计学意义(11.3 ± 3.5% vs 6.3 ± 4.0%,p <0.01)。然而,在 10 周随访时,FMD 改善至 10.4 ± 3.4%,且与基线相比,10 周随访时的 FMD 无差异(11.3 ± 3.5% vs 10.4 ± 3.4%,p = 0.26)。重复测量方差分析证实了 TMZ 组和对照组之间 FMD 差异的显著性(p <0.01)。总之,TRCAG 后 TMZ 治疗可减轻桡动脉内皮功能障碍。这可能对冠状动脉旁路移植术后桡动脉导管产生积极影响。